Stated Preferences for Attributes of a CYP2C19 Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario

BACKGROUND: Pharmacogenetic (PGx) testing identifies pharmacotherapeutic risks to permit personalized therapy. Identifying the genetic profile of patients with acute coronary syndrome (ACS) who are considered for therapy with clopidogrel (P2Y(12) receptor blockers) and acetylsalicylic acid (ASA) con...

Descripción completa

Detalles Bibliográficos
Autores principales: Bereza, Basil G, Coyle, Doug, So, Derek Y, Kadziola, Zbigniew, Wells, George, Grootendorst, Paul, Papadimitropoulos, Emmanuel A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090184/
https://www.ncbi.nlm.nih.gov/pubmed/32256091
http://dx.doi.org/10.2147/CEOR.S234298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090184/
https://www.ncbi.nlm.nih.gov/pubmed/32256091
http://dx.doi.org/10.2147/CEOR.S234298

Ejemplares similares